Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus fulvestrant after prior CDK4/6 inhibitor therapy in HR-positive/HER2-negative advanced breast cancer
2024-513372-18-00Phase 2Authorised
- Sponsor
- Consorzio Oncotech
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and fulvestrant in breast cancer, sponsored by Consorzio Oncotech. Primary endpoints: Overall response rate, Progression-free survival and 3 more. Planned start Oct 2019; status: authorised.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-513372-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513372-18-00.